A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Alterome Therapeutics, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Tizona Therapeutics, Inc
Genentech, Inc.
NKGen Biotech, Inc.
Eli Lilly and Company